Steris’ (STE) “Buy” Rating Reiterated at Stephens
Stephens reissued their buy rating on shares of Steris (NYSE:STE) in a research report report published on Thursday. They currently have a $125.00 price target on the medical equipment provider’s stock.
Separately, Zacks Investment Research downgraded Steris from a buy rating to a hold rating in a research report on Tuesday, May 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $100.86.
NYSE STE traded up $0.09 during trading on Thursday, hitting $114.83. The stock had a trading volume of 472,267 shares, compared to its average volume of 435,918. The company has a market cap of $9.70 billion, a P/E ratio of 27.67 and a beta of 1.14. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.65 and a quick ratio of 1.97. Steris has a twelve month low of $82.88 and a twelve month high of $117.48.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 27th. Investors of record on Wednesday, August 29th will be paid a dividend of $0.34 per share. This is a boost from Steris’s previous quarterly dividend of $0.31. The ex-dividend date is Tuesday, August 28th. This represents a $1.36 annualized dividend and a yield of 1.18%. Steris’s payout ratio is presently 29.88%.
In related news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, July 13th. The stock was sold at an average price of $110.50, for a total transaction of $1,105,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Walter M. Rosebrough, Jr. sold 10,697 shares of the business’s stock in a transaction that occurred on Tuesday, May 29th. The stock was sold at an average price of $102.91, for a total value of $1,100,828.27. Following the sale, the chief executive officer now owns 52,573 shares of the company’s stock, valued at approximately $5,410,287.43. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,703 shares of company stock valued at $4,922,274. 2.38% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of the stock. Hanson & Doremus Investment Management purchased a new stake in Steris in the first quarter valued at approximately $140,000. ARP Americas LP purchased a new stake in Steris in the second quarter valued at approximately $212,000. Empirical Finance LLC purchased a new stake in Steris in the second quarter valued at approximately $216,000. Ausdal Financial Partners Inc. purchased a new stake in Steris in the second quarter valued at approximately $218,000. Finally, Zions Bancorporation acquired a new position in shares of Steris in the first quarter valued at approximately $200,000. Hedge funds and other institutional investors own 90.28% of the company’s stock.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Further Reading: Earnings Per Share
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.